ArticleCureus2025
Effects of Equol on Hand Osteoarthritis in Perimenopausal Women: A Pilot Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Thematic Narrative Review of Osteoarthritis Risk Factors Across the Female Life Course.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHand pain in women has recently been reported as a symptom of menopause, and the sudden decrease in estrogen levels may be responsible for joint pain in the hand. We therefore hypothesized that intake of the estrogen analog equol (4',7-isoflavandiol) would improve pain resulting from osteoarthritis of the hand in menopausal women. We evaluate the efficacy of equol intake in improving pain and disabilities of daily living caused by hand osteoarthritis in perimenopausal women.
methodsWomen aged 45-60 years with hand pain were recruited for provisional registration (n=148). Hand osteoarthritis was diagnosed with radiography according to the Kellgren-Lawrence grading system. Excluded from the study were patients whose laboratory data indicated they had rheumatoid arthritis, thyroid disorders, or naturally possessed equol. Finally, 104 participants were registered for the protocol therapy, and we recorded visual analogue scale (0-100 mm) data on the movement and Disabilities of the Arm, Shoulder, and Hand (DASH) score after 12 weeks of equol intake versus baseline.
resultsChange in visual analogue scale on movement after 12 weeks of equol intake was -34.0 mm relative to baseline (
conclusionsThis is the first prospective clinical trial of an equol supplement as a treatment for pain caused by hand osteoarthritis. Visual analogue scale on movement improved with a statistically significant difference. The improvement was observed within 1-3 months after intake of equol. The DASH score also showed significant improvement. Equol is suggested to improve hand pain, upper limb function, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.